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Background. Clinical guidelines advise against prescribing more than one antipsychotic with limited exceptions.
Despite this, surveys continue to report high antipsychotic polypharmacy rates. The aim of the study was to investigate
the eﬀectiveness of a multi-faceted intervention in reducing prescribing of antipsychotic polypharmacy on general adult
psychiatry wards, compared with guidelines alone.
Method. A pragmatic cluster randomized controlled trial recruited 19 adult psychiatric units (clusters) from the South
West of England. Participants were all ward doctors and nurses. The multi-faceted intervention comprised: an
educational/CBT workbook; an educational visit to consultants ; and a reminder system on medication charts.
Results. The odds of being prescribed antipsychotic polypharmacy in those patients prescribed antipsychotic medi-
cation was signiﬁcantly lower in the intervention than control group when adjusted for confounders (OR 0.43, 95% CI
0.21–0.90, p=0.028). There was considerable between-unit variation in polypharmacy rates and in the change in rates
between baseline and follow-up (5 months after baseline).
Conclusion. The intervention reduced levels of polypharmacy prescribing compared to guidelines alone although the
eﬀect size was relatively modest. Further work is needed to elicit the factors that were active in changing prescribing
behaviour.
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Introduction
There is very little evidence regarding eﬃcacy of
combining antipsychotics in the treatment of schizo-
phrenia and there are a number of theoretical risks
involved in such practice (Freudenreich & Goﬀ, 2002;
Stahl, 2002). Several national guidelines on the treat-
ment of schizophrenia have advised against the
general use of more than one antipsychotic for the
treatment of schizophrenia (Canadian Psychiatric
Association, 1998; NICE, 2002; McGorry et al. 2003 ;
APA, 2004). Despite this a UK cross-sectional survey
in 1998 of in-patient wards found a rate of anti-
psychotic polypharmacy of 48% (Harrington et al.
2002). Similar high rates have also been found in in-
ternational studies (Ereshefsky, 1999).
There is widespread recognition that dissemination
of guidelines and research evidence alone does not
change behaviour nor ensure sustainable changes in
practice (Bero et al. 1998) and therefore implemen-
tation strategies are needed. The evidence on the
eﬀectiveness of diﬀerent strategies to promote the
implementation of research ﬁndings or clinical prac-
tice guidelines suggests that interventions most likely
to be eﬀective include: educational outreach visits
(‘academic-detailing’), computerized and manual re-
minders and interactive educational meetings (Oxman
et al. 1995 ; Bero et al. 1998) ; as well as multi-faceted
approaches (Bero et al. 1998 ; Wensing et al. 1998).
Trials that address the speciﬁc barriers to change and
embrace psychological models of behaviour change
appear to be a theoretically attractive option (Chilvers
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et al. 2002). There have been no guideline implemen-
tation trials in the ﬁeld of psychiatry in the UK and
indeed a recent article suggested the need for such a
trial focusing on antipsychotic polypharmacy (Ito et al.
2005).
The aim of the DEBIT (Developing Evidence-Based
Implementation Trial) study was to evaluate the
eﬀectiveness of a multi-faceted intervention to reduce
inappropriate antipsychotic polypharmacy prescrib-
ing on psychiatric in-patient wards compared with
guideline dissemination alone.
Method
Study design
We recruited four local mental health Trusts (service
provider organizations) in the South West of England
based upon their geographic proximity to the re-
search base in Bristol. They covered a mixed urban
and rural area with a population of y4 million
people. The study received full multi-centre ethics
approval. Consent for the study was obtained from
each Trust’s Medical Director and Chief Executive
(acting as ‘guardians’ of the cluster). The study was
adopted by each Trust’s clinical governance (quality
assurance programme) committee, the Trusts receiv-
ing guidance from the research team as required.
There were 19 acute psychiatric units (each with
two or more wards) that admitted general adult
psychiatry patients within these four Trusts. Wards
that had solely a specialist psychiatry function (e.g.
rehabilitation and forensic psychiatry wards) were
excluded from the study but all other wards, including
wards whose function was designated psychiatric
intensive care (PICUs) and high dependency (HDUs)
were eligible. Individual consent to examine medi-
cation charts was obtained from all but one of the
consultant psychiatrists who admitted patients to
these wards.
We used a cluster randomized design as the inter-
vention was aimed at doctors and nurses but the
outcome measures were taken from individuals under
the care of these clinicians. Our unit of randomiza-
tion (cluster) was the acute psychiatric unit. We
chose the unit rather than individual wards in order
to avoid contamination of results caused by staﬀ
moving between the diﬀerent wards in the same unit.
To ensure that the control and intervention groups
were balanced with respect to factors likely to inﬂu-
ence the outcome, stratiﬁed randomization was used
based upon size of unit, measured as number of
beds [divided into a binary variable, large (>40 beds)
or small (f40 beds)] and by the four Trusts. From
our preparatory prescribing survey we found a large
variation in prescribing patterns. Allocation to con-
trol and intervention was by random numbers gener-
ated by L.M. (using a calculator’s random number
generator function), who was blind to the identity
of these units. The timetable for the trial was de-
signed to coincide with the 6-monthly rotation of
psychiatric senior house oﬃcers in order to limit
the potential for contamination caused by doctors
moving between units. Recruitment of the Trusts
and units occurred in October 2003 and baseline
measures were taken in February 2004. The inter-
vention occurred between March and July 2004, with
follow-up measures taken in July 2004. Participants
were all qualiﬁed medical and nursing staﬀ working
on the wards involved. Participants were poten-
tially aware of which group (control or intervention)
they were allocated to due to the nature of the
intervention.
Intervention
The design of the intervention adhered to the Medical
Research Council (MRC) guidance on complex inter-
ventions (MRC, 2000). The ‘modelling phase’ of the
intervention was based on a review of the literature
and our previous qualitative work, interviewing con-
sultant psychiatrists and observation on two general
adult wards (Barley et al. in press). This work ident-
iﬁed the need to develop an intervention aimed at
teams of professionals (nurses and doctors), as pre-
scribing decisions were found to be inﬂuenced by
multi-disciplinary team members and not made in
isolation by individual consultant psychiatrists even
though the nurses in our units were not yet able to
prescribe. The intervention was multi-faceted as sug-
gested by a number of reviews of implementation
strategies (Bero et al. 1998 ; Wensing et al. 1998).
For the ﬁrst part of the intervention, an educational
outreach or ‘academic-detailing’ approach was used
(Soumerai & Avorn, 1990). This involved a 30-minute
structured personal visit to consultant psychiatrists by
a specially trained clinical psychiatric pharmacist. The
structure of the visit was based on the social marketing
principles of ‘academic-detailing’, described by
Soumerai & Avorn (1990). This included the use of
graphical material, reinforcement of key messages and
the use of prepared counter-arguments arising from
previous interviews with consultant psychiatrists
(Barley et al. in press). The pharmacist read prepared
literature reviews of the current evidence and then
received 2 days’ training in academic-detailing and
associated marketing techniques facilitated by A.T.
and a local pharmaceutical company trainer. The
pharmacist completed ‘encounter forms’ after every
visit that were reviewed regularly for ﬁdelity to the
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structure by A.T. and G.H. Due to the large distances
involved, it became clear that it was not possible for
all consultants to receive a follow-up visit in the period
of the intervention. Therefore, the intervention con-
sultants were randomly allocated, using a random
number generator, for either a brief follow-up visit or
telephone call to review progress on agreed targets.
For the second part of the intervention a workbook
for both doctors and nurses was developed. This con-
tained educational material and speciﬁc cognitive
techniques to challenge polypharmacy. The cognitive
behavioural techniques were based upon the prin-
ciples of reducing risk taking behaviours (Forensic
Psychology Practice Ltd, 1999; Rawson, 1999).
Cognitive challenges to polypharmacy prescribing
were identiﬁed from the rationales used by clinicians
to justify polypharmacy (Barley et al. in press). A range
of strategies as alternatives to polypharmacy was
oﬀered. The workbook was piloted on a local forensic
psychiatry ward for time of completion (around
1 hour), ease of understanding and relevance to prac-
tice resulting in slight adaptations. The distribution of
the workbook to all doctors and qualiﬁed nurses was
coordinated by the ward manager. A brief feedback
form was included at the back of the workbook for
return, so that a measure of the completion rate might
be calculated. Continuing Professional Development
certiﬁcates were given on workbook completion.
A ‘booster’ pamphlet was sent 8 weeks after distri-
bution of the workbook.
For the third part of the intervention, a medication
chart reminder system was developed. Ward phar-
macists applied removable reminder stickers to medi-
cation charts when patients were prescribed more
than one antipsychotic. Medication charts were scru-
tinized weekly and reminder stickers were removed if
polypharmacy was no longer prescribed. Ward phar-
macists were given a short training on the application
of the reminder system. All the stickers were removed
3 weeks before the post-intervention primary outcome
measure was collected to avoid biasing the data col-
lectors.
Polypharmacy was deﬁned as prescription of more
than one antipsychotic medication [either as regular,
as required (‘prn’) or once only medication]. Anti-
psychotic medication was deﬁned by the relevant
edition of the British National Formulary ( Joint
Formulary Committee, 2003, 2004).
Control units
In order to compare simple dissemination with our
intervention, we developed a guideline on anti-
psychotic polypharmacy from a range of evidence-
based sources, including the National Institute for
Clinical Excellence (NICE) guidelines on the treatment
and management of schizophrenia (NICE, 2002). This
was disseminated to all doctors and nurses in both
control and intervention clusters as per normal dis-
semination route for each Trust after baseline data was
collected.
Outcome measures
The primary outcome measure was antipsychotic
polypharmacy prescribing rates for each unit (cluster).
Information was collected from patients’ medication
charts using a 1-day cross-sectional survey of anti-
psychotic prescribing pre- and post-intervention. All
in-patients being prescribed any antipsychotic medi-
cation on the day of the surveys were included.
Independent auditors collected the anonymized data
using a pre-designed data-collection sheet. A list of
antipsychotic drugs to be included in the audit was
produced using the appropriate edition of the British
National Formulary (Joint Formulary Committee,
2003, 2004). The auditors were Trust employees, who
were not part of the research team, and were blind to
randomization at baseline but not at follow-up and
were aware of the purpose of the study. The auditors
were given training in the correct collection of data
and auditor reliability was checked by duplicating
15% of records. A questionnaire measuring nurses’
and doctors’ beliefs about polypharmacy was the sec-
ondary outcome measure and will be reported in a
future publication.
Sample size and data analysis
Power calculations were based on data from a large
retrospective case note survey in a local mental health
Trust on antipsychotic polypharmacy, undertaken
during 2001/2002 (Sipos, 2004). In this study we found
a cross-sectional antipsychotic polypharmacy rate of
52%. Sample size was based on the assumption of : a
reduction of antipsychotic polypharmacy rates from
50% to 25% in the intervention group with no change
in the control group; 90% power to detect a statisti-
cally signiﬁcant diﬀerence with a type I error rate of
0.05 in a two-tailed test of diﬀerences between pro-
portions. As the study was cluster-randomized we
took account of this design eﬀect. We used the case-
note survey (Sipos, 2004) to estimate an intra-class
correlation coeﬃcient (ICC) of 0.027 (95% CI 0–0.086).
We calculated we would need 226 patients or 18 units
based on an average of 13 observations per unit.
Primary and secondary analyses were undertaken
using a pre-speciﬁed analysis plan. The primary out-
come was analysed using a unit-level weighted re-
gression analysis (Donner & Klar, 2000). First, we
calculated the ICC using baseline patient-level data,
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second, the unit (cluster) level data at baseline was
used to calculate the weight for each unit using the
formula of Donner & Klar (2000, p. 88). The sub-
sequent regression models were estimated on the
cluster-level data using the logarithm of the poly-
pharmacy rate in each unit at post-intervention as the
dependent variable. We used an unadjusted model
(Model A) which included stratifying variables (size of
unit and Trust) as covariates, and a model (Model B)
which also adjusted for the baseline proportion of
antipsychotic polypharmacy in each unit. Additional
post-hoc explanatory analyses not included in the pre-
speciﬁed plan were undertaken to further adjust for
variations in case-mix. Variations between units were
adjusted for by inclusion of a covariate measuring
the proportion of specialist beds (mostly PICU and
HDU beds) in each unit (Model C). Variations in case-
mix change across units over the study period were
adjusted for by inclusion of covariates measuring
change between baseline and post-intervention for (i)
those who were male, (ii) age (at survey time point),
(iii) median length of stay (up to survey point)
(Models D and E). All analyses were undertaken using
Stata version 8.0 (StataCorp, College Station, TX,
USA).
Results
Participants and patients
There were 474 patients prescribed at least one anti-
psychotic in the baseline survey and 488 at follow-up.
More patients were prescribed at least one anti-
psychotic in the intervention arm units than the con-
trol arm units both in the baseline and follow-up
surveys. Of the participants, 112 doctors and nurses
left during our intervention period (47 from the con-
trol and 65 from the intervention units) (Fig. 1).
Characteristics of units
The characteristics of these units are shown in Table 1.
There were more specialist beds in the intervention
group units but otherwise the groups were reasonably
balanced between the trial arms.
The baseline and follow-up characteristics of the
patients whose medication charts were sampled in the
control and intervention units are shown in Table 2
along with the corresponding rates of antipsychotic
polypharmacy. Patients were younger, more likely to
be male and detained under the Mental Health Act
(although this information was not available from all
units) in both baseline and post-intervention survey in
the intervention arm. This may have been due to the
higher number of specialist intensive care/high de-
pendency beds in the intervention arm which may be
more likely to admit young male patients detained
under the Mental Health Act.
There was a higher proportion of polypharmacy at
baseline in the intervention group (13% greater than
the control group). There was a decrease in prescribed
polypharmacy rates in the intervention units (7.4%)
and an increase in prescribed polypharmacy rates in
the control units (7.0%) with an overall 14.4% diﬀer-
ence in change between the two time periods.
There was considerable variation in the change
proportions for the intervention units with all but
three units showing a reduction in polypharmacy
(ranging from a reduction of 26% to and an increase of
7%). There was similar variation in the control units
(ranging from an increase of 38% to a decrease of 10%)
with only two units having a lower polypharmacy
proportion than at baseline (see Table 3).
Weighted regression analysis
The intra-class correlation for polypharmacy rates at
baseline was 0.036 (95% CI 0–0.083). The adjusted
odds ratio (accounting for stratifying variables of unit
size and Trust) of being prescribed antipsychotic
polypharmacy in the intervention group was esti-
mated as 0.74 (95% CI 0.35–1.56, p=0.40). With ad-
justment for baseline polypharmacy rates, the odds
ratio was estimated as 0.43 (95% CI 0.21–0.90,
p=0.028).
Further adjustment for the proportion of specialist
beds in each unit, and for change in case-mix
measured by change in length of stay increased the
magnitude of the estimated eﬀect and its statistical
signiﬁcance. Model E further adjusted for change in
case-mix by gender and age, and similarly the eﬀect
size was not greatly altered with the results of the
model still being signiﬁcant at the 0.05 level. These
analyses are shown in Table 4.
Process monitoring
For the educational outreach component the mental
health pharmacist was able to visit 51/55 (92.7%) of the
consultants in the intervention units at least once, of
these 24 (43.6%) had a follow-up visit or phone call.
The average time spent per consultant was 31.7 min
(range 20–60 min). The numbers returning the feed-
back form gave an estimate of how many people
completed the workbook. This was 50% with pro-
portionally more nurses than doctors completing the
workbook feedback form (52% compared to 45% for
doctors). There was also a space for free text feedback
on the workbook feedback form. This feedback was
mostly favourable, but was not quantiﬁable. We also
performed a 1-day random check of the coverage of
the reminder system. The percentage of charts where
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stickers were appropriately used when patients were
prescribed antipsychotic polypharmacy was 61%
(Trust range 45.2–100%). The check of the reliability of
the Trusts’ data collectors in using the photocopied
medication charts, in terms of correctly coding poly-
pharmacy, was 100%.
Discussion
Our multi-faceted intervention, aimed at ward doctors
and nurses, signiﬁcantly reduced the odds of being
prescribed antipsychotic polypharmacy, compared
with a control group who received a set of guidelines.
However, the eﬀect size was modest and must be
evaluated in the light of a relatively intensive inter-
vention package.
Multi-faceted interventions, especially those ad-
dressing speciﬁc barriers to change, appear to be
the most eﬀective method of improving professional
practice (Bero et al. 1998 ; MRC, 2000). A review of in-
terventions to change doctors’ prescribing behaviour
suggests that this may be less clear for prescribing
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Fig. 1. Flow of in-patient units, patients (for outcome survey) and participants through the trial.
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behaviour alone (Gill et al. 1999). It has been suggested
that a more ‘psychological approach’ to designing
trials should take into account the literature on be-
haviour change (Chilvers et al. 2002). As part of the
preparation for this trial we therefore examined bar-
riers to change in consultants and nurses and how
prescribing decisions are made using qualitative
methods (MRC, 2000). We then incorporated these
into both a social marketing technique and a cognitive
behavioural approach.
Both academic-detailing and the use of reminder
systems have a fairly robust evidence base in terms of
implementing change in clinical practice and in pre-
scribing behaviour (Grimshaw et al. 2002; Thomson
O’Brien et al. 1997). What is novel to this trial is the
adoption of a psychological model of prescribing with
analogies to the stages-of-change model (Prochaska &
DiClemente, 1986). Using a workbook we attempted
to provide a cognitive rationale for understanding
polypharmacy, incorporating targeted cognitive chal-
lenges and behavioural experiments.
Implementation strategies in the area of prescribing
have traditionally been aimed at pharmacists and
doctors (Van Eijk et al. 2001). Our preparatory work
highlighted the role played by nurses in the prescrib-
ing process and our approach of targeting both nurses
and doctors appears to be novel in this ﬁeld. Feedback
data showed the interventions were well received.
Generalizability
The cross-sectional rate of polypharmacy at baseline in
this study (42.2%) is similar to the ﬁndings of the
Royal College of Psychiatrist’s multi-centre UK-wide
audit, which reported that 48% of all patients pre-
scribed more than one antipsychotic medication on a
1-day survey in 1998 (Harrington et al. 2002). Our
clusters were all from the South West of England but
we have no reason to believe that prescribing practices
are signiﬁcantly diﬀerent in other parts of the country.
Indeed the Trusts involved covered a large geo-
graphical area and had a mixture of urban and rural
catchment areas. Similar rates in in-patient settings
have also been found by others researchers both in the
UK and internationally (Ereshefsky, 1999; Taylor et al.
2000 ; Centorrino et al. 2002) although their appears to
be some variation between diﬀerent units (Harrington
et al. 2002).
The approach of utilizing existing clinical govern-
ance strategies in this study suggests that the eﬀect of
this intervention may be generalizable to other Trusts
without being too expensive or labour-intensive. Our
Table 1. Characteristics and comparisons of the units (clusters) involved in the trial by control and intervention arms
Control Intervention
Number of units 9 10
Mean bed numbers/unit size
Overall 39 (17–63) 38.2 (16–65)
Trust A (range) 47.5 (33–63) 42.25 (28–65)
Trust B (range) 28.5 (17–40) 43 (34–48)
Trust C (range) 53 (53–53) 36 (36–36)
Trust D (range) 25.5 (25–26) 24 (16–32)
Stand-alone PICU units (beds) 2 (12) 3 (35)
Total PICU/HDU beds 15 60
Total specialist beds 18 86
Mean number of specialist beds
(range)
3.44 (0–12) 7.80 (0–21)
Mean staﬀ/bed (range) 0.85 (0.65–1.59) 0.92 (0.53–1.33)
Mean doctor/bed (range) 0.27 (0.08–0.47) 0.28 (0.12–0.56)
Mean nurse/bed
(range)
0.58 (0.35–1.12) 0.65 (0.38–0.86)
Stand-alone psychiatric unit/part
of general hospital
4/5 4/6
Mean Townsend deprivation score
(range)
x0.24 (x5.57 to 10.87) x0.25 (x6.73 to 14.19)
Units with dedicated ward clinical
pharmacy services
5 6
PICU, Psychiatric intensive care units ; HDU, high-dependency units.
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interventions, with the exception of the educational
outreach (which could be provided by Trust pharma-
cists with additional training) were relatively low cost.
However the coverage of the intervention did depend
to some extent on the sophistication of the clinical
governance mechanisms in each Trust.
Limitations of the study
The main limitation of the study was the cross-
sectional nature of the primary outcome measure. This
was highlighted by the increase in the control group
polypharmacy rate, which may be an artefact of the
sampling method. The magnitude and statistical sig-
niﬁcance of the net intervention eﬀect is in part due
to these increased polypharmacy rates in the control
group, This was an unexpected ﬁnding [particularly
given the stability of rates found locally over a
6-month period by Sipos (2004)] which may, in whole
or part, be attributed to regression to the mean
and should be interpreted with caution. However, the
additional post-hoc explanatory analyses did not ﬁnd
any attenuation of the intervention eﬀect when change
in case-mix between baseline and post-intervention
samples was included in the models. Additionally the
eﬀect of the intervention appeared to be strengthened
when the imbalance in the proportion of specialist
beds between the control and intervention arms was
adjusted for. Ideally multiple and longer term follow-
up measurements would need to be taken to dis-
entangle intervention eﬀects from other variations, but
this was not possible within the timescale and budget
of the project. This would also have proved diﬃcult
due to fact that many of the junior doctors receiving
the intervention would have moved units at the end
of the intervention and provided potential contami-
nation eﬀects in other units. Follow-up measurements
would also help to distinguish whether the eﬀect is
sustained over time and not a temporary phenom-
enon. It must be stressed, however, that the results
presented are from the a priori pre-speciﬁed analysis
plan. We were not able to distinguish between
Table 2. Characteristics of the patients whose charts were audited in the control and intervention arms at baseline and post-intervention
and percentages of prescribed antipsychotic polypharmacy in control and intervention groups (with associated 95% conﬁdence
intervals accounting for clustering)
Control Intervention
Baseline survey
Age (yr) (n=202) (n=264)
Mean (S.D.) 43.6 (16.0) 40.0 (14.1)
Sex (n=202) (n=268)
Male 47.0 47.8
Female 53.0 52.2
Mental Health Act status (n=199) (n=255)
Detained 37.6 48.6
Informal 62.3 51.8
Length of admission in days (n=201) (n=252)
Median (S.D.) 52 (338.8) 50 (147.6)
Percentage polypharmacy (n=204) (n=270)
(95% CI corrected for clustering) 34.8 (22.9–46.7) 47.8 (41.8–53.8)
Post-intervention survey
Age (yr) (n=211) (n=250)
Mean (S.D.) 42.4 (15.6) 42.2 (13.3)
Sex (n=220) (n=258)
Male 50.0 63.6
Female 50.0 37.4
Mental Health Act status (n=167) (n=207)
Detained 47.3 54.6
Informal 52.7 45.4
Length of admission in days (n=185) (n=250)
Median (S.D.) 40 (101.8) 48.5 (179.5)
Percentage polypharmacy (n=220) (n=260)
(95% CI corrected for clustering) 41.8 (30.8–52.8) 40.4 (27.0–53.8)
Numbers in parentheses demonstrate available data for each parameter (values are percentages unless otherwise speciﬁed).
The DEBIT trial 711
patients who were sampled in both surveys (as they
had not been discharged or were readmitted) but we
were able to estimate that this was a small percentage
(around 5%) of the total and therefore unlikely to
greatly bias the eﬀect of the intervention.
There were unequal rates of polypharmacy in con-
trol and intervention groups at baseline. This was
adjusted for in the analysis, but because of time con-
straints of completing the trial during a junior-doctor
6-monthly rotation period, this could not be taken into
Table 3. Proportions of patients prescribed antipsychotic polypharmacy (with respective numbers) for each unit in the control and
intervention group (and for all units in each group) at baseline and post-intervention
Baseline
(proportion)
No. of
patients
Post-intervention
(proportion)
No. of
patients
Control
Unit 1 0.50 14 0.55 22
Unit 2 0.36 14 0.43 14
Unit 3 0.48 42 0.54 37
Unit 4 0.36 36 0.26 42
Unit 5 0.46 13 0.54 13
Unit 6 0.50 20 0.48 23
Unit 7 0.09 33 0.24 37
Unit 8 0.21 14 0.41 17
Unit 9 0.22 18 0.60 15
All units 0.35 204 0.42 220
Intervention
Unit 1 0.50 20 0.37 19
Unit 2 0.36 11 0.36 14
Unit 3 0.39 23 0.40 25
Unit 4 0.38 29 0.32 31
Unit 5 0.58 26 0.64 25
Unit 6 0.48 29 0.30 20
Unit 7 0.58 50 0.65 48
Unit 8 0.39 31 0.13 31
Unit 9 0.52 31 0.39 33
Unit 10 0.45 20 0.21 14
All units 0.48 270 0.40 260
Table 4.Weighted regression analysis models
OR 95% CI p value
Model A 0.79 0.39–1.57 0.47
Stratifying variables, only (unit size and Trust)
Model B 0.43 0.21–0.90 0.028
Stratifying variables and baseline polypharmacy rate
Model C 0.29 0.13–0.68 0.008
Stratifying variables, baseline polypharmacy
rate and proportion of specialist beds
Model D 0.27 0.10–0.71 0.014
Stratifying variables, baseline polypharmacy rate, proportion
of specialist beds and change in median length of stay
Model E 0.23 0.05–0.95 0.045
Stratifying variables, baseline polypharmacy rate, proportion of
specialist beds and change in median length of stay, gender and age
OR, Odds ratio ; CI, conﬁdence interval.
Models D and E estimated using data from only 18 units since length-of-stay data not available for one unit (a control unit).
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account during randomization. Our data collectors
were not blinded at post-intervention to whether the
unit was an intervention or control unit, but they were
independent of the study group and therefore had
limited incentive to bias a positive result. Our re-
liability check of the data collection process also
showed high accuracy. There was variable uptake of
parts of the intervention in some units and only 50% of
the staﬀ in the intervention group sent back an evalu-
ation form on the workbook (although the actual
numbers completing the workbook may have been
greater). As the trial was multi-faceted we aimed to
inﬂuence the prescribing culture through a number of
avenues but we acknowledge that getting staﬀ to par-
ticipate in this part of the intervention was diﬃcult
and may need further measures to improve this. This
variable uptake may be a reason for the more modest
eﬀect given a relatively intensive intervention.
Findings in relation to literature
Whilst many studies have examined interventions to
reduce prescribing behaviour in other specialities
(Gill et al. 1999 ; Freemantle et al. 2002), few studies
have looked at interventions to change prescribing
behaviour in the ﬁeld of psychiatry. Gill et al. (1999)
reviewed the literature on changing doctors’ prescrib-
ing behaviour and extracted all randomized control
trials that dealt exclusively with physician prescribing
and/or with professional intervention. They identiﬁed
ﬁve studies in the area of psychiatry mostly set in
the USA. Two of these were related to prescribing,
the others to wider-reaching quality-improvement
initiatives in depression and old-age psychiatry.
A controlled trial of academic-detailing to reduce
prescribing of antipsychotic drugs in nursing homes
(Ray et al. 1987) showed no eﬀect, the authors citing
other factors in the nursing home as a potential reason
for this negative result. However, Avorn et al. (1992)
were able to use educational materials and audit and
feedback to reduce the prescription of ‘psychoactive
drugs’ in a similar population. Berings et al. (1994)
were able to demonstrate a reduction in benzodiaz-
epine prescription using a combination of drug infor-
mation and outreach, but the setting was in general
practice and not in psychiatry.
Future work and implications
We have demonstrated that our multi-faceted inter-
vention is eﬀective. It is often diﬃcult to deﬁne the
‘active ingredient’ when implementing complex in-
terventions (MRC, 2000), we now need to investigate
which of the components of this intervention was
most important in inﬂuencing prescribing behaviour.
The large diﬀerence in change in some units compared
to others warrants further work as to whether broad
contextual factors as well as the individual are
important. We also plan to further explore the eﬀect
of the intervention on the patterns of prescribed and
administered polypharmacy.
A recent survey by the UK mental health charity
Rethink (Hogman & Sandamas, 2000) highlighted
patients’ concerns regarding antipsychotic prescrib-
ing, the side-eﬀects experienced and the consequent
eﬀects on their lives. We believe that interventions
such as this can inﬂuence the local prescribing cultures
towards the standards of good practice that will ben-
eﬁt patient care.
Clinical implications
(1) A multi-faceted intervention embedded in local
clinical governance mechanisms can reduce anti-
psychotic polypharmacy prescribing on adult
psychiatric wards.
(2) Such interventions should include doctors, nurses
and pharmacists.
(3) Large variations in prescribing change between
units suggests that local political and cultural
issues are also important in the prescribing process
and should be addressed by further studies.
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